SCHEMBL1891491

SCHEMBL1891491

CCc1csc(NC(=O)c2c(O)cc(C)n(C)c2=O)n1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
ALDH1A1 P00352 2/20 0.51
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 3/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPSR1 Q6W5P4 4/20 0.42
KDM4E B2RXH2 1/20 0.42
PDE5A O76074 1/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417679 0.86 MAPT (0.51) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL1886903 0.81 RAB9A (0.48) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL1890213 0.78 ALDH1A1 (0.50) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL1889947 0.76 RAB9A (0.51) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL1888774 0.76 RAB9A (0.51) SMN1; SMN2ALDH1A1NPC1RAB9AHTT
SCHEMBL1891165 0.76 RAB9A (0.51) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL1893161 0.75 RAB9A (0.52) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL1893447 0.74 AHR (0.51) SMN1; SMN2ALDH1A1NPC1RAB9ALMNA
SCHEMBL12508094 0.72 RAB9A (0.55) SMN1; SMN2NPC1RAB9AKMT2AMEN1
SCHEMBL1892597 0.72 RAB9A (0.47) SMN1; SMN2ALDH1A1NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1887002-B1 CARBOXAMIDE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2015-08-26 EP disclosed
US-8304437-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-06 US disclosed
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME ARIMORI SADAYUKI 2011-07-14 US disclosed
US-7935716-B2 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090076063-A1 Carboxamide compound and use of the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-19 US disclosed
EP-1887002-A1 CARBOXAMIDE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076063-A1 Carboxamide compound and use of the same CBR3, SIRT2, SIRT1 SMN1; SMN2 2564/4885ALDH1A1 3016/4885NPC1 1710/4885
US-20110172276-A1 CARBOXAMIDE COMPOUND AND USE OF THE SAME CBR3, SIRT2, SIRT1 SMN1; SMN2 2564/4885ALDH1A1 3016/4885NPC1 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.